bioMérieux

A global leader in in vitro diagnostics for over 45 years, bioMérieux has 39 subsidiaries and products sold in 150 countries. The company is committed to making personalized medicine a reality by building partnerships to develop theranostics for infectious diseases, cancer and cardiovascular diseases. Current collaborations include GSK, Merck & Co. and Ipsen. bioMérieux has made a sustained investment in high medical value biomarkers through in-house R&D programs, licensing and research collaborations. Theranostics development also leverages bioMérieux's unique hybrid business strategy: the high complexity CLIA lab of its subsidiary, bioTheranostics, allied with bioMérieux's global IVD business, supports aggressive development timelines while ensuring test availability wherever the drug is sold.